Aurora‐C kinase is a novel chromosomal passenger protein that can complement Aurora‐B kinase function in mitotic cells

Citations Over TimeTop 10% of 2004 papers

Abstract

The function of Aurora-C kinase, a member of the Aurora kinase family identified in mammals, is currently unknown. We present evidence that Aurora-C, like Aurora-B kinase, is a chromosomal passenger protein localizing first to centromeres and then to the midzone of mitotic cells. Aurora-C transcript is expressed at a moderate level albeit about an order of magnitude lower than Aurora-B transcript in diploid human fibroblasts. The level of Aurora-C transcript is elevated in several human cancer cell types. Aurora-C and Aurora-B mRNA and protein expressions are maximally elevated during the G2/M phase but their expression profiles in synchronized cells reveal differential temporal regulation through the cell cycle with Aurora-C level peaking after that of Aurora-B during the later part of the M phase. Aurora-C, like Aurora-B, interacts with the inner centromere protein (INCENP) at the carboxyl terminal end spanning the conserved IN box domain. Competition binding assays and transfection experiments revealed that, compared with Aurora-C, Aurora-B has preferential binding affinity to INCENP and co-expression of the two in vivo interferes with INCENP binding, localization, and stability of these proteins. A kinase-dead mutant of Aurora-C had a dominant negative effect inducing multinucleation in a dose-dependent manner. siRNA mediated silencing of Aurora-C and Aurora-B also gave rise to multinucleated cells with the two kinases silenced at the same time displaying an additive effect. Finally, Aurora-C could rescue the Aurora-B silenced multinucleation phenotype, demonstrating that Aurora-C kinase function overlaps with and complements Aurora-B kinase function in mitosis.

Related Papers

• → VX-680 Inhibits Aurora A and Aurora B Kinase Activity in Human Cells(2007)118 cited
• → Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase(2005)114 cited
• → CDKN1A-mediated responsiveness ofMLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors(2013)9 cited
• MLN8054, an orally active Aurora A kinase small molecule inhibitor in phase I clinical trials(2006)
• Aurora Kinase: A Target for Cancer Therapy(2020)